Congress Forces FDA to Evaluate Some ‎‎505(b)(2) Products for Therapeutic Equivalence ‎Listing in ‎Orange Book | Locke Lord LLP

For nearly forty years, the Food and Drug Administration (“FDA”) has required applicants seeking approval of “generic” or “branded generic” drugs under section 505(b)(2) of the Federal...

Related Keywords

,Locke Lord ,Drug Administration ,Federal Food ,Cosmetics Act ,Citizen Petition ,Drug Omnibus Reform Act ,Drugs Can Obtain ,Therapeutic Equivalence ,Will Review ,Eligible Drug ,Ultimate Effect ,Drug Makers ,Abbreviated New Drug Application ,